FDA Cannabis Breakthrough Therapy Designations: Complete Guide

Executive Summary

The FDA's Breakthrough Therapy designation represents the fastest regulatory pathway for cannabis-derived medicines to reach patients, yet fewer than a dozen cannabis compounds have received this status since the program's creation in 2012. This designation, established under the FDA Safety and Innovation Act, allows drug developers to work closely with the FDA through expedited development and review processes when preliminary clinical evidence demonstrates substantial improvement over existing therapies for serious or life-threatening conditions. The May 2026 designation granted to VERTANICAL's VER-01 for chronic low back pain marks a significant expansion beyond the epilepsy-focused cannabinoid drugs that previously dominated this pathway. For operators, this designation signals which therapeutic areas the FDA considers most promising for cannabis-based medicines. For investors, it identifies companies positioned to capture prescription drug market share potentially worth billions annually. For patients, it accelerates access to rigorously tested cannabis medicines that may offer relief where conventional treatments have failed.

Why This Matters

Breakthrough Therapy designations directly impact the $1.5 billion U.S. cannabinoid pharmaceutical market and determine which cannabis compounds transition from Schedule I research barriers to prescription medicine cabinets. The designation affects multiple stakeholder groups with billions of dollars and millions of patients at stake. For pharmaceutical companies developing cannabis-derived drugs, Breakthrough Therapy status reduces development timelines by an estimated 2-3 years and increases approval probability from roughly 10% to 25-30%, according to FDA data on the broader Breakthrough Therapy program. This translates to hundreds of millions in reduced development costs and earlier revenue generation. For the estimated 40 million Americans suffering from chronic pain conditions, expedited cannabis-based therapies offer alternatives to opioids, which contributed to over 80,000 overdose deaths in 2025 according to CDC provisional data. The VER-01 designation for chronic low back pain specifically addresses the most common pain condition in America, affecting approximately 80% of adults at some point in their lives and costing the U.S. economy an estimated $635 billion annually in medical treatment and lost productivity. State-licensed cannabis operators watch these designations closely because FDA approval of cannabis-derived drugs creates regulatory precedent and market competition. When the FDA approved Epidiolex in 2018, it validated cannabidiol as a legitimate medicine, indirectly strengthening arguments for broader cannabis policy reform while simultaneously creating a prescription competitor to dispensary CBD products. Investors use Breakthrough Therapy designations as leading indicators of which therapeutic areas and molecular targets show the strongest clinical evidence. Companies receiving this designation typically see immediate stock price increases of 20-40% on announcement, reflecting the improved probability of eventual approval and market entry.

Background and History

The FDA Breakthrough Therapy designation program emerged from the 2012 FDA Safety and Innovation Act, but cannabis compounds remained largely excluded until Epidiolex broke through in 2016.

Creation of the Breakthrough Therapy Pathway (2012)

Congress established the Breakthrough Therapy designation through the FDA Safety and Innovation Act, signed into law on July 9, 2012. The statute, codified at 21 U.S.C. § 356(a), created an expedited development and review process for drugs treating serious conditions where preliminary clinical evidence demonstrates substantial improvement over existing therapies. The program aimed to accelerate promising treatments to patients faster while maintaining rigorous safety and efficacy standards. The designation provides several concrete benefits: early and frequent communication between FDA and sponsor, organizational commitment involving senior FDA managers, and eligibility for rolling review and priority review. From 2012 through 2025, the FDA granted Breakthrough Therapy designation to over 800 drug development programs across all therapeutic areas, with oncology representing approximately 40% of designations.

Cannabis Research Barriers Under Schedule I (1970-2018)

Cannabis remained classified as a Schedule I controlled substance under the Controlled Substances Act of 1970, creating substantial barriers to the clinical research required for FDA drug approval. Schedule I classification requires researchers to obtain DEA registration, navigate a single-source supply system through the National Institute on Drug Abuse, and comply with extensive security and recordkeeping requirements that add significant cost and complexity to clinical trials. Despite these barriers, GW Pharmaceuticals initiated clinical development of cannabidiol for pediatric epilepsy in the early 2010s. The company conducted its pivotal trials under DEA Schedule I research protocols, demonstrating that rigorous pharmaceutical development of cannabis compounds remained possible within the existing regulatory framework, albeit at substantially higher cost and complexity than Schedule II-V substances.

Epidiolex Breakthrough Designation (2016)

On November 16, 2016, the FDA granted Breakthrough Therapy designation to GW Pharmaceuticals' cannabidiol oral solution for treatment of Dravet syndrome, a rare and severe form of childhood epilepsy. This marked the first time a cannabis-derived compound received this expedited pathway designation. The preliminary clinical evidence came from Phase 2 trials showing cannabidiol reduced seizure frequency by a median of 39% compared to placebo in patients with Dravet syndrome. The designation accelerated Epidiolex development, with the FDA working closely with GW Pharmaceuticals through the Phase 3 trial design and regulatory submission process. The collaboration exemplified how Breakthrough Therapy designation functions in practice, with quarterly meetings between sponsor and FDA reviewers to address development questions in real-time rather than through lengthy written correspondence.

Epidiolex FDA Approval (2018)

On June 25, 2018, the FDA approved Epidiolex for treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in patients two years and older. This represented the first FDA-approved drug derived from cannabis and the first approval in the Breakthrough Therapy program for a cannabis compound. The approval relied on four randomized, double-blind, placebo-controlled clinical trials involving 516 patients with either Dravet syndrome or Lennox-Gastaut syndrome. Following FDA approval, the DEA rescheduled Epidiolex specifically to Schedule V on September 27, 2018, through a final rule published at 83 FR 48950. This rescheduling applied only to FDA-approved cannabidiol drugs containing less than 0.1% THC, not to cannabidiol generally, maintaining the Schedule I status of non-FDA-approved cannabis extracts.

Expansion to Additional Indications (2019-2025)

The FDA expanded Epidiolex's approved indications to include tuberous sclerosis complex on July 31, 2020, based on additional clinical trial data. This expansion demonstrated the pathway for cannabis-derived drugs to broaden their therapeutic applications through supplemental new drug applications supported by additional clinical evidence. Between 2018 and 2025, several other cannabis-derived compounds entered clinical development with FDA engagement, though few achieved Breakthrough Therapy designation. Synthetic cannabinoids including dronabinol and nabilone had received FDA approval decades earlier for chemotherapy-induced nausea and AIDS-related anorexia, but these approvals preceded the Breakthrough Therapy program's creation.

VERTANICAL VER-01 Designation (2026)

On May 25, 2026, the FDA granted Breakthrough Therapy designation to VERTANICAL's VER-01 for treatment of chronic low back pain. This designation represented a significant expansion of cannabis-based Breakthrough Therapy designations beyond rare pediatric epilepsy into a high-prevalence chronic pain indication affecting tens of millions of Americans. The preliminary clinical evidence supporting the designation came from Phase 2 trials demonstrating VER-01's efficacy in reducing pain and improving function in patients with chronic low back pain who had inadequate response to conventional therapies. The VER-01 designation signals FDA openness to cannabis-derived therapies for chronic pain conditions, a therapeutic area where opioid alternatives carry substantial public health value. The designation's timing coincides with ongoing federal discussions about cannabis rescheduling and growing acceptance of cannabis-based medicines in mainstream medical practice.

Key Players

Food and Drug Administration (FDA)

The FDA's Center for Drug Evaluation and Research administers the Breakthrough Therapy designation program and evaluates all new drug applications for cannabis-derived medicines. The agency maintains that cannabis-derived products must undergo the same rigorous clinical trial process as any other drug, regardless of cannabis's legal status in individual states. The FDA's position, articulated in multiple public statements, holds that state-legal cannabis products cannot make therapeutic claims without FDA approval based on adequate and well-controlled clinical investigations. Dr. Patrizia Cavazzoni serves as Director of the Center for Drug Evaluation and Research as of 2026, overseeing the review divisions that evaluate cannabis-derived drug applications. The FDA's Division of Anesthesia, Analgesia, and Addiction Products specifically reviews pain-related applications including VER-01.

Drug Enforcement Administration (DEA)

The DEA controls cannabis scheduling under the Controlled Substances Act and regulates the manufacture, distribution, and research use of controlled substances. The agency's decisions on scheduling directly impact the regulatory pathway for cannabis-derived drugs. While the DEA rescheduled FDA-approved Epidiolex to Schedule V in 2018, cannabis itself remains Schedule I as of May 2026, though rescheduling proceedings initiated in 2024 remain under consideration. The DEA also administers the research registration system that governs who can conduct clinical trials with Schedule I substances. This registration requirement has historically limited the number of researchers able to conduct cannabis clinical trials, though the agency expanded the number of authorized cannabis manufacturers for research purposes beginning in 2021.

VERTANICAL

VERTANICAL, the company developing VER-01, represents a new generation of cannabis pharmaceutical companies pursuing FDA approval through rigorous clinical trials rather than operating in state-licensed markets. The company's Breakthrough Therapy designation for chronic low back pain positions it to potentially capture significant market share in the estimated $18 billion U.S. pain management pharmaceutical market. VER-01's specific formulation, dosing, and cannabinoid composition remain proprietary, though the Breakthrough Therapy designation indicates preliminary clinical evidence of substantial improvement over existing therapies. The company must still complete Phase 3 clinical trials and submit a New Drug Application to achieve FDA approval, a process typically requiring 3-5 years even with Breakthrough Therapy designation.

GW Pharmaceuticals (Jazz Pharmaceuticals)

GW Pharmaceuticals, acquired by Jazz Pharmaceuticals in 2021 for $7.2 billion, pioneered the FDA approval pathway for cannabis-derived drugs with Epidiolex. The company's experience navigating Schedule I research requirements, conducting placebo-controlled trials of cannabis compounds, and achieving FDA approval established the regulatory roadmap that subsequent cannabis pharmaceutical developers follow. Jazz Pharmaceuticals reported Epidiolex net product sales of $804 million in 2025, demonstrating the commercial viability of FDA-approved cannabis-derived medicines. The company continues to explore additional indications for cannabidiol and develop other cannabinoid-based therapies.

National Institute on Drug Abuse (NIDA)

NIDA, part of the National Institutes of Health, historically controlled the only legal source of cannabis for federally authorized research through its contract with the University of Mississippi. This monopoly created supply constraints and quality concerns that researchers argued hindered cannabis drug development. The DEA's expansion of authorized manufacturers beginning in 2021 reduced NIDA's gatekeeping role, though the institute remains a significant funder of cannabis research and a voice in policy discussions.

Patient Advocacy Organizations

Organizations including Americans for Safe Access, the Epilepsy Foundation, and the U.S. Pain Foundation have advocated for expanded access to cannabis-based medicines and supported FDA approval pathways as a means to ensure product quality and consistency. These groups generally support both the FDA approval process for pharmaceutical cannabinoids and broader access to state-legal cannabis, viewing the pathways as complementary rather than competing approaches to patient access.

Legal and Regulatory Framework

Cannabis-derived drugs navigate a complex intersection of the Controlled Substances Act, the Federal Food, Drug, and Cosmetic Act, and the FDA Safety and Innovation Act, creating a unique regulatory pathway distinct from both conventional pharmaceuticals and state-legal cannabis. The Controlled Substances Act, codified at 21 U.S.C. § 801 et seq., establishes five schedules of controlled substances based on medical use, abuse potential, and safety. Cannabis remains in Schedule I, defined as substances with high abuse potential, no currently accepted medical use, and lack of accepted safety for use under medical supervision. This classification creates a legal paradox: the FDA can approve cannabis-derived drugs demonstrating accepted medical use, which then triggers DEA rescheduling of that specific approved drug product while cannabis generally remains Schedule I. The Federal Food, Drug, and Cosmetic Act, codified at 21 U.S.C. § 301 et seq., grants the FDA authority to regulate drugs and requires that new drugs demonstrate safety and efficacy through adequate and well-controlled investigations before marketing. Section 505 of the Act, 21 U.S.C. § 355, establishes the new drug application process that cannabis-derived medicines must complete regardless of cannabis's status under state law. The FDA Safety and Innovation Act, enacted as Public Law 112-144 on July 9, 2012, created the Breakthrough Therapy designation in Section 902, codified at 21 U.S.C. § 356(a). The statute defines breakthrough therapy as a drug that "is intended, alone or in combination with 1 or more other drugs, to treat a serious or life-threatening disease or condition" and for which "preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on 1 or more clinically significant endpoints." The statute requires the FDA to take actions to expedite development and review, including holding meetings with the sponsor throughout development, providing timely advice to the sponsor, involving senior managers and experienced review staff, and assigning a cross-disciplinary project lead. These requirements create a more collaborative development process than standard drug development pathways. FDA regulations at 21 CFR Part 312 govern investigational new drug applications, which researchers must file before conducting clinical trials of cannabis-derived compounds. These regulations apply equally to Schedule I substances, though the additional DEA registration requirements for Schedule I research create practical barriers not present for other scheduled substances. The DEA's research registration regulations, codified at 21 CFR Part 1301, require researchers working with Schedule I substances to obtain DEA registration, maintain extensive security measures, and comply with detailed recordkeeping requirements. These requirements add substantial cost to cannabis clinical trials compared to trials of non-scheduled substances or substances in Schedules II-V. State laws do not affect the FDA approval pathway for cannabis-derived drugs. A company can conduct FDA-authorized clinical trials of cannabis compounds in any state regardless of that state's cannabis laws, as federal law preempts state law for federally authorized research. Conversely, state-legal cannabis programs do not satisfy FDA requirements for drug approval, as the FDA does not recognize state authorization as a substitute for federal clinical trial requirements.

Market and Business Implications

Breakthrough Therapy designations for cannabis compounds create a bifurcated market where FDA-approved prescription cannabinoids compete with state-legal cannabis products, with the prescription market potentially reaching $5-8 billion annually by 2030. The prescription cannabinoid market, currently dominated by Epidiolex with approximately $800 million in annual sales, represents a small fraction of the estimated $30 billion state-legal cannabis market. However, prescription cannabinoids offer several competitive advantages: insurance coverage, physician prescribing within conventional medical practice, consistent dosing and quality control, and legal access in all 50 states regardless of state cannabis laws. VER-01's Breakthrough Therapy designation for chronic low back pain targets a substantially larger patient population than rare pediatric epilepsy. Approximately 25-30 million Americans suffer from chronic low back pain, with the condition representing the leading cause of disability worldwide according to the Global Burden of Disease Study. If VER-01 achieves FDA approval and captures even 5% of this patient population at an estimated annual treatment cost of $3,000-5,000, the drug could generate $3.75-7.5 billion in annual revenue. For multi-state operators and state-licensed cannabis companies, FDA-approved cannabis drugs present both threat and opportunity. The threat lies in potential market cannibalization, as patients who might otherwise purchase cannabis products from dispensaries instead obtain prescriptions for FDA-approved drugs covered by insurance. The opportunity lies in potential partnerships, licensing arrangements, or acquisitions that allow cannabis companies to participate in the pharmaceutical market. Several large cannabis companies have established pharmaceutical development divisions or partnerships to pursue FDA approval pathways. These efforts reflect recognition that the pharmaceutical market offers higher margins, intellectual property protection, and access to institutional capital markets that remain largely closed to plant-touching cannabis businesses operating under state law. Investment capital flows reflect the distinction between pharmaceutical cannabinoid development and state-licensed cannabis operations. Pharmaceutical companies developing cannabis-derived drugs can access traditional venture capital, institutional investors, and eventually public markets without the banking restrictions that affect state-licensed cannabis operators. VERTANICAL's Breakthrough Therapy designation likely triggered significant institutional investor interest and positioned the company for additional funding rounds at substantially higher valuations. The designation also impacts wholesale cannabis markets indirectly. As pharmaceutical companies conduct large-scale clinical trials requiring consistent cannabis-derived active pharmaceutical ingredients, they create demand for GMP-grade cannabis cultivation and extraction. This pharmaceutical-grade supply chain operates separately from state-licensed recreational and medical markets, with higher quality standards and regulatory requirements but also premium pricing. Insurance coverage represents a critical market differentiator. Epidiolex gained coverage from most major insurers and state Medicaid programs, making it accessible to patients who could not afford out-of-pocket costs of $30,000-40,000 annually. VER-01, if approved, would similarly seek insurance coverage, potentially making prescription cannabinoid therapy for chronic pain accessible to millions of patients who currently cannot afford state-legal cannabis products or prefer to obtain medicine through conventional medical channels. The competitive landscape includes both other cannabis-derived drugs in development and conventional pain medications. VER-01 would compete with opioids, NSAIDs, muscle relaxants, and other pain management approaches. The drug's value proposition centers on efficacy comparable to or better than existing therapies with a potentially superior safety profile, particularly regarding addiction risk compared to opioids.

What Experts Say

Medical researchers, regulatory experts, and industry analysts view cannabis Breakthrough Therapy designations as validation of rigorous pharmaceutical development while debating implications for broader cannabis policy reform. Dr. Igor Grant, Director of the Center for Medicinal Cannabis Research at the University of California San Diego, has stated in published research that FDA approval of cannabis-derived drugs demonstrates that cannabis compounds can meet the same evidentiary standards as other medicines. According to Grant's research published in medical journals, the challenge lies not in whether cannabis compounds can be effective medicines, but in conducting the costly, time-consuming clinical trials required to demonstrate safety and efficacy to FDA standards. The Epilepsy Foundation, which advocated for expanded access to cannabidiol before Epidiolex's approval, has described FDA approval as providing patients with consistent, quality-controlled medicine with known dosing. The organization's public statements emphasize that FDA approval does not preclude other forms of access but provides an additional pathway that offers certainty about product content and appropriate dosing. Regulatory attorneys specializing in cannabis law note that Breakthrough Therapy designations create a pathway for cannabis compounds to achieve medical legitimacy within the federal regulatory system without requiring broader cannabis rescheduling. This pathway allows incremental progress on cannabis policy through drug-by-drug approval rather than requiring comprehensive legislative reform. Industry analysts at investment research firms have published reports projecting that the prescription cannabinoid market could reach $8-12 billion annually by 2030 as additional compounds achieve FDA approval for various indications. These projections assume 5-8 FDA-approved cannabinoid drugs reaching market by 2030, targeting indications including chronic pain, anxiety disorders, sleep disorders, and inflammatory conditions. Pain management specialists have expressed interest in FDA-approved cannabinoid options as alternatives to opioids, particularly for chronic pain conditions where long-term opioid use carries significant addiction and overdose risks. According to statements from the American Academy of Pain Medicine, rigorously studied cannabinoid therapies could fill an important gap in the pain management toolkit if clinical trials demonstrate efficacy and acceptable safety profiles. Patient advocates have expressed mixed views on pharmaceutical cannabinoid development. Some view FDA approval as essential for ensuring product quality and enabling insurance coverage, while others worry that pharmaceutical companies will use intellectual property protections to limit access and charge premium prices for compounds that patients can currently obtain from state-legal dispensaries at lower cost. Cannabis industry executives have stated in investor presentations and industry conferences that pharmaceutical cannabinoid development validates cannabis as medicine and may accelerate broader policy reform by demonstrating cannabis's medical utility. However, these executives also acknowledge that FDA-approved drugs may compete with dispensary products for certain patient populations.

What's Next

VERTANICAL must complete Phase 3 clinical trials and submit a New Drug Application, a process typically requiring 3-5 years even with Breakthrough Therapy designation, while broader cannabis rescheduling proceedings may alter the regulatory landscape. The immediate next step for VER-01 involves designing and initiating Phase 3 clinical trials in consultation with the FDA. Breakthrough Therapy designation provides VERTANICAL with frequent FDA interaction to optimize trial design, select appropriate endpoints, and address potential regulatory issues before they become obstacles to approval. The company will likely need to enroll 500-1,000 patients across multiple clinical sites in randomized, double-blind, placebo-controlled trials demonstrating VER-01's efficacy and safety for chronic low back pain. Phase 3 trials for pain indications typically measure outcomes including pain intensity reduction, functional improvement, quality of life measures, and safety parameters over treatment periods of 12-24 weeks or longer. The FDA will require demonstration of statistically significant improvement over placebo on co-primary endpoints, likely including both pain reduction and functional improvement measures. Assuming successful Phase 3 trials, VERTANICAL would submit a New Drug Application, a comprehensive document including all clinical trial data, manufacturing information, proposed labeling, and risk-benefit analysis. The FDA's review process, even with priority review available through Breakthrough Therapy designation, typically requires 6-10 months from submission to approval decision. If approved, VER-01 would require DEA scheduling determination. Following the Epidiolex precedent, the DEA would likely schedule VER-01 in Schedule II-V based on its abuse potential assessment, removing it from Schedule I restrictions while maintaining controlled substance status. This scheduling would allow prescription dispensing through conventional pharmacy channels with appropriate controls. Parallel to VER-01's development, the DEA's cannabis rescheduling proceeding initiated in 2024 continues through the administrative law judge process. If cannabis moves from Schedule I to Schedule III as proposed in the Department of Health and Human Services recommendation, it would not directly affect already-approved drugs like Epidiolex or future approvals like VER-01, but it would substantially reduce barriers to conducting clinical trials of new cannabis-derived compounds. Several other cannabis-derived compounds are in earlier-stage clinical development for indications including post-traumatic stress disorder, autism spectrum disorder, and various pain conditions. Companies developing these compounds will watch VER-01's progress closely, as successful approval would further validate the FDA pathway for cannabis medicines and potentially accelerate investor interest in the sector. The FDA is expected to issue additional guidance documents addressing cannabis and cannabinoid product development, building on existing guidance for botanical drug products. These guidance documents would provide clarity on issues including acceptable cannabis source material, standardization requirements, and clinical trial design considerations specific to cannabinoid drugs. Insurance coverage negotiations will begin immediately upon any FDA approval, with manufacturers seeking formulary inclusion from major pharmacy benefit managers and state Medicaid programs. Coverage decisions will significantly impact market uptake, as out-of-pocket costs for novel pharmaceuticals often exceed $1,000 monthly without insurance coverage. State medical cannabis programs may need to address how FDA-approved cannabis drugs interact with state-legal medical cannabis access. Some states may consider whether FDA approval of a cannabis drug for a specific condition affects that condition's eligibility for medical cannabis recommendations, though most states are likely to maintain separate pathways allowing patients to choose between prescription drugs and state-legal cannabis products.

Further Reading

• FDA Safety and Innovation Act, Public Law 112-144 (July 9, 2012) - https://www.congress.gov/bill/112th-congress/senate-bill/3187
• 21 U.S.C. § 356(a) - Breakthrough Therapy designation statutory text - https://www.law.cornell.edu/uscode/text/21/356
• FDA Guidance for Industry: Expedited Programs for Serious Conditions – Drugs and Biologics (May 2014) - https://www.fda.gov/regulatory-information/search-fda-guidance-documents/expedited-programs-serious-conditions-drugs-and-biologics
• Epidiolex Approval Letter and Review Documents, FDA (June 25, 2018) - https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000TOC.cfm
• DEA Final Rule: Schedules of Controlled Substances: Placement in Schedule V of Certain FDA-Approved Drugs Containing Cannabidiol, 83 FR 48950 (September 28, 2018) - https://www.federalregister.gov/documents/2018/09/28/2018-21121/schedules-of-controlled-substances-placement-in-schedule-v-of-certain-fda-approved-drugs-containing
• Controlled Substances Act, 21 U.S.C. § 801 et seq. - https://www.dea.gov/drug-information/csa
• Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 301 et seq. - https://www.fda.gov/regulatory-information/laws-enforced-fda/federal-food-drug-and-cosmetic-act-fdc-act
• FDA Statement on Signing of the Agriculture Improvement Act of 2018 (December 20, 2018) - https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-signing-agriculture-improvement-act-2018
• Jazz Pharmaceuticals Annual Report (Form 10-K) for fiscal year 2025 - https://investors.jazzpharma.com
• National Academies of Sciences, Engineering, and Medicine: The Health Effects of Cannabis and Cannabinoids (2017) - https://www.nationalacademies.org/our-work/the-health-effects-of-cannabis-and-cannabinoids